Market Research Report
Asia Pacific Western Blotting Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||823180|
|Published||Content info||85 Pages
Delivery time: 2-3 business days
|Asia Pacific Western Blotting Market Forecast 2019-2027|
|Published: April 15, 2019||Content info: 85 Pages||
The western blot testing technique is a highly complex procedure for identifying and measuring the amount of a specific protein in a mixed extract and is mostly used as in testing for pathogenic, viral, etc. protein from a blood sample.
Asia Pacific western blotting market generated a revenue of $XX million in 2018 and is projected to reach $XX million by 2027, at a CAGR of 6.86% in the forecast period of 2019-2027. Presence of supportive government initiatives and non-profit organizations mainly propels the growth of the Asia Pacific regional market.
In Asia-Pacific, with the growing biotechnology industry in Japan and China, there is an expected steady growth of the market in the region which is expected to boost the market in Asia-Pacific during the forecast period of 2019-2027.
The economies of China, India, Japan, South Korea, Australia and the remaining countries collectively forming the Rest of World regional segment are the major revenue contributors to the APAC market. Japan has been known as a low HIV-prevalence country with a concentrated epidemic among high-risk groups.
Also, the increasing cases of HIV aids coupled with the rising prevalence of endemic Lyme disease are boosting the western blotting market in Japan during the forecast period 2019-2027.
Bio-Rad Technologies Inc., Lumigen Inc., Rockland Immunochemicals Inc., Li-Cor Inc., GE Healthcare, Thermo Fisher Scientific Ltd., Merck KGaA, Azure Biosystems Inc., Roche Diagnostics, Advansta, PerkinElemer Inc., F. Hoffman La-Roche Ltd., Bio-Techne Corporation, Roche Diagnostics International Ltd., and, Cell Signaling Technology Inc. are the major companies operating in the market.